Mike Stenberg, LGM Pharma, outlines how GLP-1s, AI, and 505(b)(2) delivery shifts are driving pharmaceutical innovation.

The pharmaceutical industry requires rapid training to address workforce shortages for new US manufacturing facilities, ...

FDA has taken steps to embrace AI in 2025, announcing in December that it will be providing agency staff with agentic AI ...

André Cerbe, CEO of Schlafender Hase, spoke with Pharmaceutical Technology® about the disruptions the pharma industry faced ...

Managing a modern pharmaceutical supply chain is like building a house during a storm; it is no longer enough to ensure the ...

Frits Stulp, Implement Consulting, says AI and global collaboration are key to addressing patent cliffs and accelerating ...

Ultimately, these advancements suggest a more integrated ecosystem. Trusted regulatory spaces function like a communal ...

The Wegovy pill's approval signifies a shift from injectable to oral dosage forms, driven by patient preference for ...

AI-driven decision engines and intelligent orchestration layers are crucial for navigating geopolitical risks and ...

The revised EU pharmaceutical policy maintains eight-year data protection but reduces market protection to one year, ...

From a global regulatory perspective, Cytokinetics is expanding its footprint rapidly. The drug received approval in China on ...

IDMP standards aim to improve medicinal product data management but have faced delays, limiting their benefits for the life ...